Global life science and 3D biology pioneers Molecular Devices has launched a groundbreaking facility in Cardiff, dedicated to research, development and industrial-scale manufacture of organoids. Image Credit: Monmouth Scientific The organoids structures originate from human stem cells and represent organs in the body. They are instrumental in advancing drug discovery by providing human-centric models that give accurate predictions for the safety and efficacy of potential new therapeutic compounds.
The ability to produce organoids at such a large scale is unprecedented and offers the potential to streamline the drug discovery process, allowing for a rapid transition from laboratory research to medical applications and reducing the high failure rates commonly seen in clinical trials. The facility, underpinned by the firm’s proprietary bioreactor technology, is poised to revolutionise healthcare through the provision of large quantities of consistent and reproducible patient-derived organoids. The initiative aligns with the UK Government’s Life Sciences Vision, bolstering the sector, which contributes over £94 billion to the UK economy.
Sterility and contamination control To ensure the highest levels of sterility and contamination control within their new facility, Molecular Devices opted to install Guardian Class 2 Biological Safety Cabinets provided by Monmouth Scientific (Microbiological Safety Cabinets – MSCs). The need for stringent regulation i.